About
Radiopharmaceuticals
Areas of Focus
Categories
Small Molecule PharmaceuticalRadiopharmaceuticalsNorway
Team (34)
Anne Cecile Alvik
Anne Cecile Alvik
Oncoinvent
team_member
Anne Cecilie Alvik
Anne Cecilie Alvik
Oncoinvent
team_member
Anne-Kirsti Aksnes
Anne-Kirsti Aksnes
Oncoinvent
team_member
Board member
Board member
Oncoinvent
team_member
Board member / Employee representative
Board member / Employee representative
Oncoinvent
team_member
Chair
Chair
Oncoinvent
board_chair
Clinical Trials (3)
View allTotal Trials
3
As Lead Sponsor
3
As Collaborator
0
Total Enrollment
210
By Phase
PHASE2: 1PHASE1: 1PHASE1/PHASE2: 1
By Status
RECRUITING: 1ACTIVE_NOT_RECRUITING: 1COMPLETED: 1
Clinical Trials Pipeline3 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
2032
Today
Hover over trial bars to see details
Recent Trials
NCT06504147Lead Sponsor
A Study of Radspherin® in Patients with Primary Advanced Epithelial Cancer, with Peritoneal Metastasis That Are Homologous Recombination Proficient Scheduled to Undergo Neoadjuvant Chemotherapy and Interval Debulking Surgery
PHASE2Recruiting
114 participants
Started: Jun 15, 2024 · Completed: Feb 28, 2031
NCT03732768Lead Sponsor
Study of Radspherin® in Recurrent Ovarian Cancer Subjects With Peritoneal Carcinomatosis
PHASE1Active, not recruiting
49 participants
Started: Jun 8, 2020 · Completed: Aug 31, 2025
NCT03732781Lead Sponsor
Study of Radspherin® in Colorectal Carcinoma Subjects With Peritoneal Carcinomatosis Treated With HIPEC
PHASE1/PHASE2Completed
47 participants
Started: May 27, 2020 · Completed: May 14, 2025
Locations (1)
Headquarters
Oslo, Norway
Map
Loading map...